Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (551) 551
leukemia, myelogenous, chronic, bcr-abl positive - physiopathology (360) 360
hematology (200) 200
male (188) 188
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (181) 181
female (173) 173
oncology (166) 166
chronic myelogenous leukemia (160) 160
index medicus (160) 160
adult (159) 159
middle aged (149) 149
chronic myeloid-leukemia (128) 128
imatinib mesylate (118) 118
leukemia, myelogenous, chronic, bcr-abl positive - genetics (112) 112
antineoplastic agents - therapeutic use (106) 106
animals (103) 103
benzamides (98) 98
leukemia, myelogenous, chronic, bcr-abl positive - therapy (98) 98
leukemia, myelogenous, chronic, bcr-abl positive - pathology (95) 95
chronic myeloid leukemia (94) 94
leukemia (92) 92
aged (89) 89
pyrimidines - therapeutic use (83) 83
piperazines - therapeutic use (75) 75
bcr-abl (72) 72
cancer (57) 57
protein kinase inhibitors - therapeutic use (55) 55
mice (52) 52
adolescent (49) 49
imatinib (49) 49
leukemia, myelogenous, chronic, bcr-abl positive - complications (48) 48
philadelphia-chromosome (47) 47
fusion proteins, bcr-abl - genetics (45) 45
research (45) 45
antineoplastic agents - adverse effects (44) 44
cell biology (44) 44
prognosis (43) 43
apoptosis (42) 42
bone marrow transplantation (42) 42
transplantation (42) 42
acute lymphoblastic-leukemia (41) 41
cml (41) 41
pyrimidines - adverse effects (40) 40
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (39) 39
care and treatment (38) 38
hemic and lymphatic diseases (38) 38
immunology (37) 37
medicine, research & experimental (37) 37
antineoplastic agents - pharmacology (36) 36
fusion proteins, bcr-abl - metabolism (36) 36
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (36) 36
stem cells (35) 35
philadelphia chromosome (34) 34
transplantation, homologous (34) 34
child (33) 33
biochemistry & molecular biology (32) 32
protein-tyrosine kinases - antagonists & inhibitors (32) 32
piperazines - adverse effects (31) 31
bone-marrow transplantation (30) 30
disease progression (30) 30
protein kinase inhibitors - adverse effects (30) 30
treatment outcome (30) 30
genetic aspects (29) 29
leukemia, myelogenous, chronic, bcr-abl positive - blood (29) 29
pharmacology & pharmacy (29) 29
precursor cell lymphoblastic leukemia-lymphoma - physiopathology (29) 29
pyrimidines - pharmacology (29) 29
risk factors (29) 29
signal transduction (29) 29
therapy (29) 29
drug resistance, neoplasm (28) 28
chronic granulocytic-leukemia (27) 27
hematopoietic stem cell transplantation (27) 27
medicine, general & internal (27) 27
piperazines - pharmacology (27) 27
tyrosine kinase (27) 27
chronic-phase (26) 26
hematopoiesis (26) 26
mutation (26) 26
time factors (26) 26
aged, 80 and over (25) 25
bone marrow - pathology (25) 25
dasatinib (25) 25
interferon-alpha - therapeutic use (25) 25
tyrosine kinase inhibitor (25) 25
chronic myelocytic-leukemia (24) 24
medicine & public health (24) 24
neoplasms - physiopathology (24) 24
blast crisis (23) 23
bone marrow (23) 23
diagnosis (23) 23
physiological aspects (23) 23
abl tyrosine kinase (22) 22
apoptosis - drug effects (22) 22
cells (22) 22
hematopoietic stem cells - physiology (22) 22
protein kinase inhibitors - pharmacology (22) 22
tyrosine kinase inhibitors (22) 22
interferon-alpha (21) 21
k562 cells (21) 21
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (528) 528
French (12) 12
Japanese (11) 11
Chinese (6) 6
Russian (6) 6
Polish (5) 5
Spanish (3) 3
Dutch (2) 2
German (2) 2
Czech (1) 1
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
by Ren, Ruibao
Nature Reviews Cancer, ISSN 1474-175X, 03/2005, Volume 5, Issue 3, pp. 172 - 183
Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has shown remarkable clinical activity in patients with chronic myelogenous leukaemia... 
MYELOPROLIFERATIVE DISEASE | COLONY-STIMULATING FACTOR | B-CELL | C-ABL | ONCOLOGY | PHILADELPHIA-CHROMOSOME | HEMATOPOIETIC STEM-CELLS | MINIMAL RESIDUAL DISEASE | PROTEIN-TYROSINE-PHOSPHATASE | CHRONIC MYELOID-LEUKEMIA | TRANSGENIC MICE | Oncogene Proteins v-abl - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Gene Expression Regulation, Neoplastic | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Proto-Oncogene Proteins c-abl - pharmacology | Animals | Cell Transformation, Neoplastic | Genes, abl | Antineoplastic Agents - pharmacology | Mice | Benzamides | Disease Models, Animal | Care and treatment | Translocation (Genetics) | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
by Schiffer, Charles A
The New England Journal of Medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 3, pp. 258 - 265
A 28-year-old woman with recently diagnosed chronic myelogenous leukemia (CML) presents for consideration of appropriate treatment. No siblings are available... 
CYTOGENETIC RESPONSES | ACCELERATED PHASE | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | BLAST CRISIS | PATIENTS RECEIVING IMATINIB | DOMAIN MUTATIONS | MESYLATE THERAPY | WORKING PARTY | CHRONIC MYELOID-LEUKEMIA | Dasatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Piperazines - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Fusion Proteins, bcr-abl | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Adult | Female | Benzamides | Practice Guidelines as Topic | Protein-Tyrosine Kinases - antagonists & inhibitors | Case studies | Transplantation | Chronic myeloid leukemia | Health aspects | Stem cells | Bone marrow | Chromosomes | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Molecular biology of bcr-abl1-positive chronic myeloid leukemia
by Quintás-Cardama, Alfonso and Cortes, Jorge
Blood, ISSN 0006-4971, 02/2009, Volume 113, Issue 8, pp. 1619 - 1630
Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene.... 
CHRONIC MYELOGENOUS LEUKEMIA | BLAST-CRISIS CML | ABL TYROSINE KINASE | PHILADELPHIA-CHROMOSOME | HEMATOPOIETIC STEM-CELLS | BCR-ABL | CHROMOSOME-POSITIVE LEUKEMIAS | DOUBLE-STRAND BREAKS | HEMATOLOGY | IMATINIB MESYLATE THERAPY | SEQUENCE-BINDING-PROTEIN | Fusion Proteins, bcr-abl - genetics | Animals | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Molecular Biology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Signal Transduction - physiology | Fusion Proteins, bcr-abl - metabolism | Gene Expression Regulation, Leukemic - physiology | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods
by Kantarjian, Hagop and Schiffer, Charles and Jones, Dan and Cortes, Jorge
Blood, ISSN 0006-4971, 02/2008, Volume 111, Issue 4, pp. 1774 - 1780
CHRONIC MYELOGENOUS LEUKEMIA | POLYMERASE-CHAIN-REACTION | CHRONIC-PHASE | MOLECULAR RESPONSES | IN-SITU HYBRIDIZATION | CYTOGENETIC RESPONSE | QUANTITATIVE RT-PCR | DOMAIN MUTATIONS | HEMATOLOGY | INTERFERON-ALPHA THERAPY | IMATINIB MESYLATE | Chromosome Banding | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | In Situ Hybridization, Fluorescence | Enzyme Inhibitors - therapeutic use | Fusion Proteins, bcr-abl | DNA Mutational Analysis | Gene Rearrangement | Polymerase Chain Reaction | Drug Monitoring | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Bcr-Abl-mediated redox regulation of the PI3K AKT pathway
by Naughton, R and Quiney, C and Turner, S.D and Cotter, T.G
Leukemia, ISSN 0887-6924, 08/2009, Volume 23, Issue 8, pp. 1432 - 1440
Bcr-Abl causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells. In this study,... 
PI3k/Akt pathway | CHRONIC MYELOGENOUS LEUKEMIA | CELLS | ACTIVATION | TYROSINE KINASE | Bcr-Abl | SMALL GTPASE RAC | PROTEIN PHOSPHATASE 2A | protein phosphatase | REACTIVE OXYGEN | INHIBITION | ONCOLOGY | NADPH oxidase | HYDROGEN-PEROXIDE | HEMATOLOGY | NADPH OXIDASES | Reactive Oxygen Species - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Oxidation-Reduction | Humans | NADPH Oxidases - antagonists & inhibitors | Neoplasm Proteins - physiology | RNA, Small Interfering - pharmacology | Glycogen Synthase Kinase 3 beta | Proto-Oncogene Proteins c-akt - physiology | NADPH Oxidase 4 | Onium Compounds - pharmacology | Glycogen Synthase Kinase 3 - metabolism | beta Catenin - metabolism | Hydrogen Peroxide - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Protein Phosphatase 1 - antagonists & inhibitors | Fusion Proteins, bcr-abl - physiology | Myeloid Cell Leukemia Sequence 1 Protein | NADPH Oxidases - genetics | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | Apoptosis - physiology | Cell Line, Tumor - metabolism | NADPH Oxidases - physiology | Cell proliferation | Cell lines | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Gene expression | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Chronic myeloid leukaemia
by Hehlmann, Rüdiger, Prof and Hochhaus, Andreas, Prof and Baccarani, Michele, Prof and European LeukemiaNet
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9584, pp. 342 - 350
Summary Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of the genotype led to a rationally designed therapy. As a result... 
Internal Medicine | CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA | DONOR LYMPHOCYTE INFUSIONS | ABL TYROSINE KINASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | BCR-ABL | PATIENTS RECEIVING IMATINIB | TRANSFERASE INHIBITOR SCH66336 | STEM-CELL TRANSPLANTATION | ALPHA PLUS CYTARABINE | Prognosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Interferon-alpha - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Survival Rate | Piperazines - therapeutic use | Protein Kinase Inhibitors - adverse effects | Imatinib Mesylate | Piperazines - adverse effects | Randomized Controlled Trials as Topic | Stem Cell Transplantation | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Benzamides | Immunologic Factors - therapeutic use | Studies | Signal transduction | Immunization | Leukemia | Medical treatment | Older people | Clinical trials | Success | Risk factors | Binding sites
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML
by Jamieson, Catriona H.M and Ailles, Laurie E and Dylla, Scott J and Muijtjens, Manja and Jones, Carol and Zehnder, James L and Gotlib, Jason and Li, Kevin and Manz, Markus G and Keating, Armand and Sawyers, Charles L and Weissman, Irving L
The New England Journal of Medicine, ISSN 0028-4793, 08/2004, Volume 351, Issue 7, pp. 657 - 667
The mechanism of the progression of chronic myelogenous leukemia (CML) from the chronic phase to the blast phase is unknown. These researchers report the... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | IN-VITRO | ACTIVATION | CHRONIC-PHASE | BCR-ABL | BONE-MARROW | GENE-TRANSFER | BETA-CATENIN | EXPRESSION | CHRONIC MYELOID-LEUKEMIA | Blast Crisis - physiopathology | Granulocytes - cytology | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | RNA, Neoplasm | DNA-Binding Proteins - metabolism | Lymphoid Enhancer-Binding Factor 1 | Hematopoietic Stem Cells - physiology | Adult | Cytoskeletal Proteins - metabolism | Female | Colony-Forming Units Assay | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | beta Catenin | Hematopoietic Stem Cells - metabolism | Piperazines - therapeutic use | Macrophages - cytology | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Transcription Factors - metabolism | Microscopy, Confocal | Pyrimidines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Trans-Activators - metabolism | Aged | Benzamides | Fusion Proteins, bcr-abl - metabolism | Granulocytes | Stem cells | Research | Bone marrow | Leukemia | Genes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
by Zhao, Chen and Chen, Alan and Jamieson, Catriona H and Fereshteh, Mark and Abrahamsson, Annelie and Blum, Jordan and Kwon, Hyog Young and Kim, Jynho and Chute, John P and Rizzieri, David and Munchhof, Michael and VanArsdale, Todd and Beachy, Philip A and Reya, Tannishtha
Nature, ISSN 0028-0836, 04/2009, Volume 458, Issue 7239, pp. 776 - 779
Although the role of Hedgehog (Hh) signalling in embryonic pattern formation is well established(1), its functions in adult tissue renewal and maintenance... 
CHRONIC MYELOGENOUS LEUKEMIA | PATHWAYS | PROGENITORS | THERAPY | GENE | SONIC HEDGEHOG | MULTIDISCIPLINARY SCIENCES | BCR-ABL | RESISTANCE | PROLIFERATION | MECHANISMS | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Receptors, G-Protein-Coupled - metabolism | Signal Transduction | Humans | Cells, Cultured | Hedgehog Proteins - physiology | Tomatine - analogs & derivatives | Tomatine - pharmacology | Nerve Tissue Proteins - metabolism | Animals | Smoothened Receptor | Receptors, G-Protein-Coupled - antagonists & inhibitors | Veratrum Alkaloids - pharmacology | Proto-Oncogene Proteins c-abl - metabolism | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Mice | Receptors, G-Protein-Coupled - genetics | Neoplastic Stem Cells - physiology | Hedgehogs | Usage | Care and treatment | Myelocytic leukemia | Genetic aspects | Models | Nonlymphoid leukemia | Research | Drug resistance | Health aspects | Hematopoietic stem cells | Studies | Leukemia | Stem cells | Bone marrow | Cell division | Kinases | Binding sites | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The biology of CML blast crisis
by Calabretta, Bruno and Perrotti, Danilo
Blood, ISSN 0006-4971, 06/2004, Volume 103, Issue 11, pp. 4010 - 4022
Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the Philadelphia chromosome as the sole genetic abnormality into blast crisis,... 
CHRONIC MYELOGENOUS LEUKEMIA | FORKHEAD TRANSCRIPTION FACTOR | TRANSFORMED HEMATOPOIETIC-CELLS | CHRONIC GRANULOCYTIC LEUKEMIA | PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY | ACUTE LYMPHOBLASTIC-LEUKEMIA | BCR-ABL ONCOGENE | CHRONIC MYELOCYTIC-LEUKEMIA | DEPENDENT KINASE INHIBITOR | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | Blast Crisis - physiopathology | Animals | Blast Crisis - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights